
The cofounder and chief executive officer of NKILT Therapeutics discussed unique advantages of the CIR platform.

The cofounder and chief executive officer of NKILT Therapeutics discussed unique advantages of the CIR platform.

The cofounder and chief executive officer of NKILT Therapeutics discussed new preclinical data presented at WOCTC.

Raphaël G. Ognar, chief executive officer and co-founder of NKILT Therapeutics, discussed approaches to help increase patient access to cell therapies.